- Investor's Business Daily•43 minutes ago
Alkermes' antidepressant drug "clearly has blockbuster potential," Credit Suisse said Friday.
- TheStreet.com•1 hour ago
Alkermes (ALKS) said that its depression drug showed positive results in a late-stage clinical trial, prompting analysts to raise their ratings on the stock.
Alkermes plc (ALKS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||56.75 x 300|
|Ask||56.81 x 900|
|Day's Range||54.80 - 59.36|
|52wk Range||27.14 - 80.71|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-30.27|
|Avg Vol (3m)||793,376|
|Dividend & Yield||N/A (N/A)|